Steffen Böhm
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma
Gallerani E, D'Incalci M, Sala F, Cereda R, Marsoni S, de Braud F, Driessen C, Böhm S, Martinelli G, Delmonte A, Hess U, Noberasco C, Marangon E, Brunelli D, Zucchetti M, Sessa C. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. Eur J Cancer 2012; 49:290-6.
Oct 8, 2012A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma
Oct 8, 2012Eur J Cancer 2012; 49:290-6
Gallerani Elisa, D'Incalci Maurizio, Sala Federica, Cereda Roberta, Marsoni Silvia, de Braud Filippo, Driessen Christoph, Böhm Steffen, Martinelli Giovanni, Delmonte Angelo, Hess Urs, Noberasco Cristina, Marangon Elena, Brunelli Dario, Zucchetti Massimo, Sessa Cristiana
Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib
Böhm S, Hess D, Gillessen Sommer S, Brändle M. Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib. Diabetes care 2010; 33:e82.
Jun 1, 2010Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib
Jun 1, 2010Diabetes care 2010; 33:e82
Böhm Steffen, Hess Dagmar, Gillessen Sommer Silke, Brändle Michael